The early identification of high-risk individuals could lead to effective interventions that prevent heart attacks, strokes, or other CVD events, potentially offsetting the upfront costs of ApoB testing with savings from reduced emergency treatments, hospitalizations, and chronic disease management [5]. This evidence concerns the gene APOB and myocardial infarction.